274 related articles for article (PubMed ID: 24890761)
1. In vitro-in vivo correlation strategy applied to an immediate-release solid oral dosage form with a biopharmaceutical classification system IV compound case study.
Bredael GM; Bowers N; Boulineau F; Hahn D
J Pharm Sci; 2014 Jul; 103(7):2125-2130. PubMed ID: 24890761
[TBL] [Abstract][Full Text] [Related]
2. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
3. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
4. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
5. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
6. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
7. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
8. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
9. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutical classification based on solubility and dissolution: a reappraisal of criteria for hypothesis models in the light of the experimental observations.
Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):168-72. PubMed ID: 20030634
[TBL] [Abstract][Full Text] [Related]
11. The developability classification system: application of biopharmaceutics concepts to formulation development.
Butler JM; Dressman JB
J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
[TBL] [Abstract][Full Text] [Related]
12. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
Otsuka K; Shono Y; Dressman J
J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
[TBL] [Abstract][Full Text] [Related]
13. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
[TBL] [Abstract][Full Text] [Related]
14. An updated overview with simple and practical approach for developing in vitro-in vivo correlation.
Jacob S; Nair AB
Drug Dev Res; 2018 May; 79(3):97-110. PubMed ID: 29697151
[TBL] [Abstract][Full Text] [Related]
15. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL
Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504
[TBL] [Abstract][Full Text] [Related]
16. Predicting biopharmaceutical performance of oral drug candidates - Extending the volume to dissolve applied dose concept.
Muenster U; Mueck W; van der Mey D; Schlemmer KH; Greschat-Schade S; Haerter M; Pelzetter C; Pruemper C; Verlage J; Göller AH; Ohm A
Eur J Pharm Biopharm; 2016 May; 102():191-201. PubMed ID: 26955751
[TBL] [Abstract][Full Text] [Related]
17. Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms.
Akers MJ
Int J Pharm Compd; 2017; 21(1):47-56. PubMed ID: 28346198
[TBL] [Abstract][Full Text] [Related]
18. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
19. Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability.
Kakhi M; Marroum P; Chittenden J
Biopharm Drug Dispos; 2013 Jul; 34(5):262-77. PubMed ID: 23097186
[TBL] [Abstract][Full Text] [Related]
20. Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations.
Kollipara S; Ahmed T; Chougule M; Guntupalli C; Sivadasu P
AAPS PharmSciTech; 2024 May; 25(5):118. PubMed ID: 38806735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
